Photo by aaronburden from unsplash
EMPRISE is a study program on the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor (SGLT2i), in routine care across a spectrum of cardiovascular (CV) baseline risk… Click to show full abstract
EMPRISE is a study program on the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor (SGLT2i), in routine care across a spectrum of cardiovascular (CV) baseline risk using real-world data from 2 U.S. commercial and Medicare claims datasets (2014-2019). In an
Keywords:
empagliflozin;
emprise study;
effectiveness;
effectiveness safety;
comparative effectiveness
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of the American College of Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!